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Abstract
Purpose Tumor cells, including colorectal cancer (CRC),
are able to produce and release matrix metalloproteinase 9
(MMP-9) which is involved in tumor invasion and
metastasis. Natural tissue inhibitors of matrix metallopro-
teinases (TIMPs) regulate activity of MMPs and stimulate
tumor growth and malignant transformation. The aim of the
present study was to compare the clinical significance of
serum MMP-9 with TIMP-1 in the diagnosis of CRC
patients and in the differentiation between colorectal
adenoma (CA) and cancer.
Methods Serum MMP-9 and TIMP-1 were measured in 75
CRC patients, 35 CA, and 70 healthy subjects using
enzyme-linked immunosorbent assay. Concentrations of
carcinoembryonic antigen (CEA) and carbohydrate antigen
19-9 (CA 19-9) were determined by microparticle enzyme
immunoassay.
Results Serum levels of all proteins tested were significantly
higher in CRC patients than in healthy subjects. Additionally,
serum TIMP-1 was significantly higher in patients with CRC
than in CA patients. Concentrations of TIMP-1 correlated
with tumor stage, nodal involvement, presence of distant
metastases, patients' survival, and tumor resectability. Diag-
nostic sensitivity of TIMP-1 was higher (61%) than those of
other biomarkers (MMP-9, 55%; CEA, 39%; CA 19-9,
11%), and increased in combined use with MMP-9 (75%) or
CEA (73%). The areas under receiver operating characteris-
tic curves of TIMP-1 were larger than those of MMP-9.
Conclusions Our findings suggest better usefulness of
serum TIMP-1 than MMP-9 in the diagnosis of CRC,
especially in the assessment of Duke's classification of
tumor stage, survival of cancer patients, resectability of
tumor, and in the differentiation between CA and cancer.
Keywords Colorectal cancer.Colorectal adenoma.
MMP-9.TIMP-1.Tumor markers
Introduction
Colorectalcancer(CRC)isoneofthemostfrequentmalignant
tumors in the industrialized world—it is estimated as the third
leading cause of new cancer cases, as well as malignancy-
related death [1]. The largest risk of CRC development is
observed in patients with genetic predispositions or with
sporadic adenomatous polyps [2]. Colorectal carcinogenesis
is a complex, long-term, and multi-step process of malignant
transformation from normal epithelium to cancer cells, which
involves numerous genetic changes and results in various
phenotypic alterations [3]. The adenomatous polyps are
neoplastic tumors with a potential to develop into invasive
adenocarcinoma of the colon or rectum. Sequence of events
includes adenomatous polyps of the colon or rectum, through
grades of increasing dysplasia to carcinoma in situ.
Although proteolytic degradation of extracellular matrix
(ECM) is observed in many physiological conditions, it
plays a role in development of malignant tumors as a key
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shown that tumor cells, including CRC, are able to produce
and release matrix metalloproteinase 9 (MMP-9), a proteo-
lytic enzyme capable of degrading the basement membrane
and type IV collagen in the ECM. Degradation of collagen
by MMP-9 is involved both in tumor invasion and
metastasis [5]. Increased expression of this enzyme in
CRC cells was associated with enhanced invasiveness of
tumor [6]. Elevated serum or plasma levels of MMP-9 were
observed in patients with colorectal [7], gastric [8], lung
[9], and breast cancer [10].
Naturally occurring tissue inhibitors of matrix metal-
loproteinases (TIMPs) partly regulate the proteolytic activity
of MMPs. TIMP-1 binds and inhibits MMP-9 in a 1:1
stoichiometric proportion. Increased expression of TIMP-1
correlates with overexpression of MMP-9, although regula-
tionofoneoftheseproteinsbyanothermaybeanindependent
process, resulting in a local imbalance of MMP activity [11].
This lack of balance between MMPs and TIMPs is an
important factor in the development of gastrointestinal
malignancies [4]. It was demonstrated that TIMPs might
stimulate tumor growth and malignant transformation [12],
as well as inhibit tumor cell apoptosis [13]. Therefore, it was
suggested that TIMP-1 might play a dual role in the
regulation of cancer progression and metastasis.
Enhanced expression of TIMP-1 in tumor tissues was
observed in CRC [12] and breast cancer [14]. Elevated
concentrations of this protein were detected in patients with
metastatic prostate cancer and CRC [15–17]. Increased
plasma level of TIMP-1 was a significant prognostic factor
for the survival of patients with colorectal [18–21], lung [9]
and breast cancer [10].
It has been proposed that MMPs and TIMPs might play
a role not only in colorectal tumor invasion and initiation of
metastatic cascade, but also in colorectal carcinogenesis
from adenomatous polyps. The expression of MMP-9 in
CRC tissue was significantly higher in comparison with
colorectal adenoma (CA), or the normal mucosa and
staining intensity correlated with the grade of CRC [22].
Moreover, significantly higher expression of MMP-9 has
been observed in adenomas with high grade dysplasia
compared to other adenomas or normal colon tissue [22].
Tissue samples from various steps of colorectal carcino-
genesis, e.g., tubular adenomas, tubovillous adenomas,
villous adenomas, and colorectal adenocarcinomas were
examined by immunocytochemical staining for the pres-
ence of MMP-9 and TIMP-1. The immunolocalization of
MMP-9 and TIMP-1 increased gradually from tubular
adenomas to villous adenomas, and in carcinomas in situ,
a definite positive expression of these proteins was shown.
This increasing expression of MMP-9 and TIMP-1 coin-
cides with a multi-step process of colonic tumorigenesis
[23]. Moreover, the activity of MMP-9 determined in
zymography was significantly higher in CRC tissue than
in adenomas or normal mucosa [24].
The aim of the present study was to compare the clinical
significance of serum MMP-9 with TIMP-1 measurement
in the diagnosis of CRC patients, as well as in the
differentiation between CA and cancer. We determined the
concentrations of MMP-9 and TIMP-1 in the sera of CRC
patients in relation to clinico-pathological features of cancer
and serum levels of classical tumor markers: carcinoem-
bryonic antigen (CEA) and carbohydrate antigen 19-9 (CA
19-9). Moreover, we assessed the diagnostic sensitivity and
areas under receiver operating characteristic (ROC) curves
for all the proteins tested.
Material and methods
Patients
The study included a total number of 180 subjects: 75
previously untreated CRC patients, 35 CA patients, and 70
healthy subjects. The subjects were CRC patients (28
women and 47 men, aged 27–83 years) and CA patients
(13 women and 22 men, aged 32–78 years) diagnosed from
September 2003 to May 2006 and operated at the Second
General Surgery Department of the Białystok Medical
University Hospital; the control group comprised of 20
women and 15 men, aged 20–69 years. Physical examina-
tion, blood tests, chest x-rays, abdominal ultrasound, and
computed tomography were used in the clinical diagnosis
of the patients. The diagnosis of CRC or CAwas confirmed
by microscopic examination of the tumor samples obtained
during colonoscopy, biopsy, and/or surgery. The subjects
who had suffered a heart attack or heart failure were not
included in the study. Moreover, the patients with extra-
intestinal tumors and those after preoperative radio-
chemotherapy were excluded from the study.
Sixty-seven CRC patients underwent surgical tumor
resection, while eight patients had non-resectable tumors.
The staging of cancer was based on a routine postoperative
histopathological analysis and clinical assessment accord-
ing to Duke's classification [25]. For statistical analysis, the
CRC patients were divided into three groups: 28 cancer
patients in stage B, 27 patients in stage C, and 20 patients
in stage D, and then sub-divided into: three groups
depending on the infiltration of the bowel wall (T2, T3,
and T4), four groups depending on nodal involvement (N0,
N1, N2, and N3), two groups depending on the presence of
distant metastases (M0 and M1). Twelve CRC patients died
of cancer during the 2-year observation period, whereas 63
patients survived. The number of patients in the analyzed
subgroups is shown in Table 1. The study was approved by
the local ethics committee, the study number is R-I-002/
1178 Int J Colorectal Dis (2010) 25:1177–1184285/2009. All the patients gave their informed consent to
participate in the study.
Biochemical analyses
Bloodsamplesfromallthepatientsweredrawnbeforesurgical
treatment. None of the CRC patients had received chemo- or
radiotherapy before blood sample collection. To standardize
clotting conditions, all sera were separated within 1 h after
blood collection, aliquoted and stored at −80°C until assayed.
Serum levels of MMP-9 and TIMP-1 were measured
using enzyme-linked immunosorbent assay kits (R&D
Systems, Abingdon, England) according to the manufac-
turer's instructions. The serum samples were diluted
100-fold before determination. The manufacturer of assay
kits referred to the intra-assay coefficient of variation (CV
%) as 1.9% at MMP-9 mean concentration of 2.04 ng/mL,
SD=0.039 and as 3.9% at TIMP-1 mean concentration of
1.27 ng/mL, SD=0.05. Serum concentrations of CEA and
carbohydrate antigen 19-9 (CA 19-9) were measured by
microparticle enzyme immunoassay kits (Abbott, Chicago,
Illinois). The intra-assay CV for CEA is reported by the
manufacturer of the assay kits to be 4.9% at a mean
concentration of 2.2 ng/mL, SD=0.11 and the intra-assay
CV% for CA 19-9, 4.7% at a mean concentration of
38.2 IU/mL, SD=1.80. The reference cut-off values for
tumor markers (the 95th percentile) were established
previously in our department by examining blood sera of
healthy volunteers [26]. The cut-off points were 4.0 ng/mL
for CEA and 30.0 IU/mL for CA 19-9. The cut-off points
for serum levels of MMP-9 (480 ng/mL) and TIMP-1
(203 ng/mL) were determined using Microsoft Office Excel
software. In the ROC report generated by this program, the
cut-off value corresponds to the highest accuracy (minimal
false-negative and false-positive results).
Statistical analysis
A preliminary statistical analysis (χ2 test) revealed that serum
levels of MMP-9, TIMP-1, CEA, and CA 19-9 did not follow
a normal distribution. Therefore, nonparametric statistical
analyses were used. The stages B1 and B2 were analyzed as
one group (stage B), whereas stages C1 and C2—as stage C
because of small numbers of patients in the particular
subgroups. The Mann–Whitney U test was used to compare
the two groups in each category (the controls versus CRC or
CA patients; M0 versus M1 group; the group of patients who
survived versus patients who died of CRC; resectable tumors
versus nonresectable). Differences between more than two
groups (e.g., stage B, C, D; or T2, T3, T4; or N0, N1, N2,
N3) were compared using ANOVA on ranks (Kruskal–Wallis
tests). If significant differences were found, the post hoc
Dwass–Steele–Critchlow–Fligner test was conducted to de-
termine which groups were different. Differences were
considered statically significant with p values below 0.05.
Moreover, we calculated diagnostic criteria such as percent-
age of elevated levels (diagnostic sensitivity) and area under
the ROC curve (AUC) for the MMP-9, TIMP-1, and tumor
markers. Statistical analyses were carried out using the
STATISTICA 5.1 PL program (StatSoft Inc., Tulsa, OK).
Diagnostic criteria and the ROC curves were calculated using
MedCalc statistical software (MedCalc Software, Mariakerke,
Belgium) and Microsoft Office Excel program (Microsoft
Corporation, Redmond, WA).
Results
Serum concentrations of MMP-9, TIMP-1, CEA, and CA
19-9 in colorectal cancer and colorectal adenoma patients
Concentrations (median and range) of MMP-9, TIMP-1,
and tumor markers in the sera of CRC and adenoma
Table 1 Characteristics of colorectal cancer patients
Variable analyzed Number
of patients
Group Colorectal cancer 75
Colorectal adenoma 35
Control group 70
Duke's stage B1 3
B2 25
C1 19
C2 8
D2 0
TNM classification stage II 28
stage III 27
stage IV 20
Tumor localization colon 54
rectum 21
Bowel wall infiltration (T factor) T2 4
T3 56
T4 15
Nodal involvement (N factor) N0 29
N1 21
N2 16
N3 9
Distant metastases (M factor) M0 55
M1 20
Resectability of tumor Resectable 67
Nonresectable 8
Patients' survival Alive 63
Dead 12
Int J Colorectal Dis (2010) 25:1177–1184 1179patients, as well as in healthy subjects are presented in
Table 2. Serum levels of all proteins tested were higher in
CRC patients than in CA patients and healthy controls. The
differences between CRC patients and control group were
significant for all measurands, but between CRC and CA
patients, only concentrations of TIMP-1 and CEA were
significant. Moreover, levels of MMP-9 and TIMP-1 were
significantly higher in adenoma group in comparison with
healthy subjects. The differences between the analyzed
groups were confirmed in Dwass–Steel–Critchlow–Fligner
post hoc tests, and statistical significance was found for the
comparison of MMP-9 levels in CA patients and healthy
controls; for CEA, in comparison of CRC with adenoma
patients and CRC with control group; but for TIMP-1 level,
for all analyzed pairs.
The concentrations of MMP-9 and TIMP-1 in patients
with colonic cancer were higher, but levels of tumor
markers are lower than those in rectal cancer subgroup.
The differences were significant only for serum MMP-9.
Levels of MMP-9, TIMP-1, and tumor markers corre-
lated with the Duke's stage and were the highest in the sera
of CRC patients with stage D. The differences between
cancer stages were significant only for TIMP-1 in Kruskal–
Wallis test (p=0.003) and were confirmed in post hoc
Dwass–Steel–Critchlow–Fligner test for comparison be-
tween patients with Duke's stage B and D, as well as
between stage C and D of CRC patients.
Serum levels of MMP-9, TIMP-1, CEA, and CA 19-9
in CRC patients in relation to clinico-pathological
variables of tumor
Table 3 presents concentrations of MMP-9, TIMP-1, CEA,
and CA 19-9 in the sera of CRC patients in relation to
clinico-pathological variables of tumor. Serum levels of all
proteins tested varied according to bowel wall infiltration
(T factor) and were the highest in the T4 subgroup,
although these differences were not significant.
Serum levels of all biomarkers tested related to nodal
involvement, but only the serum TIMP-1 levels revealed
significant correlation with N factor (p=0.019), and were
the highest in the N3 subgroup. The statistical significance
of these differences were confirmed in post hoc Dwass–
Steel–Critchlow–Fligner test for comparison between N0
and N3 CRC patients.
Similarly, in patients with distant metastases, concen-
trations of all measurands were increased in comparison
with the M0 subgroup. The differences were found to be
significant for TIMP-1 (p=0.001) and CEA (p=0.043) in
Mann–Whitney test.
Moreover, serum levels of all proteins tested increased in
subgroup of CRC patients who died of cancer during the
observation period, although the differences were statisti-
T
a
b
l
e
2
M
e
d
i
a
n
(
r
a
n
g
e
)
o
f
s
e
r
u
m
l
e
v
e
l
s
o
f
M
M
P
-
9
,
T
I
M
P
-
1
,
a
n
d
t
u
m
o
r
m
a
r
k
e
r
s
i
n
c
o
l
o
r
e
c
t
a
l
a
d
e
n
o
m
a
a
n
d
c
o
l
o
r
e
c
t
a
l
c
a
n
c
e
r
p
a
t
i
e
n
t
s
V
a
r
i
a
b
l
e
t
e
s
t
e
d
M
M
P
-
9
(
n
g
/
m
L
)
p
T
I
M
P
-
1
(
n
g
/
m
L
)
p
C
E
A
(
n
g
/
m
L
)
p
C
A
1
9
-
9
(
I
U
/
m
L
)
p
G
r
o
u
p
C
o
l
o
r
e
c
t
a
l
c
a
n
c
e
r
5
3
0
(
8
9
–
2
,
0
0
0
)
a
0
.
0
2
1
*
*
2
2
1
(
1
2
5
–
7
4
2
)
a
,
b
<
0
.
0
0
1
*
*
2
.
3
(
0
.
2
–
1
,
9
8
2
.
0
)
a
,
b
<
0
.
0
0
1
*
*
4
.
1
(
0
.
0
–
4
,
4
8
8
.
9
)
a
0
.
1
2
6
C
o
l
o
r
e
c
t
a
l
a
d
e
n
o
m
a
5
1
8
(
1
6
2
–
1
,
5
8
5
)
a
1
8
3
(
1
3
5
–
3
4
4
)
a
0
.
9
(
0
.
3
–
6
.
9
)
1
.
7
(
0
.
0
–
2
0
6
.
0
)
C
o
n
t
r
o
l
g
r
o
u
p
3
9
1
(
6
0
–
2
,
6
9
6
)
1
6
3
(
6
1
–
2
7
6
)
0
.
7
(
0
.
0
–
3
.
9
)
2
.
0
(
0
.
0
–
2
4
.
0
)
T
u
m
o
r
l
o
c
a
l
i
z
a
t
i
o
n
C
o
l
o
n
6
7
5
(
8
9
–
2
,
0
0
0
)
a
0
.
0
2
4
*
2
2
6
(
1
2
5
–
6
1
6
)
a
0
.
4
1
9
2
.
3
(
0
.
2
–
1
,
9
8
2
.
0
)
a
0
.
5
9
5
3
.
2
(
0
.
0
–
4
,
4
8
8
.
9
)
0
.
6
5
4
R
e
c
t
u
m
3
4
3
(
1
5
7
–
2
,
0
0
0
)
2
0
2
(
1
3
0
–
7
4
2
)
a
2
.
4
(
0
.
3
–
1
,
0
3
0
.
0
)
a
4
.
6
(
0
.
0
–
7
7
.
4
)
T
u
m
o
r
s
t
a
g
e
D
u
k
e
'
s
B
5
3
0
(
8
9
–
1
,
8
7
9
)
0
.
4
4
1
2
1
1
(
1
3
8
–
6
0
1
)
a
0
.
0
0
3
*
*
2
.
2
(
0
.
2
–
4
7
.
8
)
a
0
.
1
2
6
2
.
8
(
0
.
0
–
1
6
.
3
0
)
0
.
2
5
9
D
u
k
e
'
s
C
4
5
6
(
1
2
2
–
1
,
2
5
5
)
2
0
2
(
1
2
5
–
3
9
8
)
a
2
.
2
(
0
.
5
–
3
6
6
.
6
)
a
2
.
8
(
0
.
0
–
1
9
.
3
)
D
u
k
e
'
s
D
6
0
0
(
1
0
0
–
2
,
0
0
0
)
3
0
4
(
1
3
2
–
7
4
2
)
a
5
.
4
(
0
.
5
–
1
,
9
8
2
.
0
)
a
6
.
1
(
0
.
0
–
4
,
4
8
8
.
9
)
a
a
s
t
a
t
i
s
t
i
c
a
l
l
y
s
i
g
n
i
f
i
c
a
n
t
w
h
e
n
c
o
m
p
a
r
e
d
t
o
c
o
n
t
r
o
l
g
r
o
u
p
b
s
t
a
t
i
s
t
i
c
a
l
l
y
s
i
g
n
i
f
i
c
a
n
t
w
h
e
n
c
o
m
p
a
r
e
d
t
o
C
A
g
r
o
u
p
*
p
<
0
.
0
5
,
s
t
a
t
i
s
t
i
c
a
l
l
y
s
i
g
n
i
f
i
c
a
n
t
(
M
a
n
n
–
W
h
i
t
n
e
y
t
e
s
t
)
*
*
p
<
0
.
0
5
,
s
t
a
t
i
s
t
i
c
a
l
l
y
s
i
g
n
i
f
i
c
a
n
t
(
K
r
u
s
k
a
l
–
W
a
l
l
i
s
A
N
O
V
A
t
e
s
t
)
1180 Int J Colorectal Dis (2010) 25:1177–1184cally significant for TIMP-1 (p<0.001). Similar observa-
tions were made in CRC patients with nonresectable tumors
compared to those with resectable ones.
The diagnostic criteria for MMP-9, TIMP-1, CEA, and CA
19-9 in CRC patients
The percentage of elevated concentrations of proteins tested
in CRC patients (diagnostic sensitivity) is presented in
Fig. 1. The diagnostic sensitivity of serum TIMP-1 levels
was higher than those of MMP-9, CEA, and CA 19-9. The
combined use of MMP-9 or TIMP-1 improved the
diagnostic sensitivity of tumor markers. The frequency of
increased concentrations was the highest for the combina-
tion of MMP-9 with TIMP-1 or MMP-9 with CEA levels
(75%). The TIMP-1 area under ROC curve (0.8319) was
higher than the AUC for other markers (Fig. 2). Addition-
ally, we analyzed AUC for differentiation between CRC
and CA patients. The highest values were obtained for CEA
(0.7735) and TIMP-1 (0.7469) (Fig. 3).
Discussion
Matrix metalloproteinases are the enzymes involved in
tumor progression and may be produced by stromal or
tumoral cells [4]. Their natural tissue inhibitors (TIMPs) are
induced in stromal cells to regulate the proteinase reactions
[27]. Increased expression of MMPs and TIMPs plays a key
role in CRC invasion and/or metastasis [28]. It was
observed that the levels of MMP-9 and TIMP-1 were
elevated in CRC patients in relation to healthy controls [7,
16–18]. Therefore, in order to further evaluate the clinical
value of serum MMP-9 and TIMP-1, we determine and
compare the diagnostic usefulness of these proteins.
The concentrations of MMP-9 and TIMP-1 in the sera of
75 CRC patients were assessed in relation to clinico-
pathological features of tumor such as Duke's stage, tumor
location, bowel wall infiltration (T factor), involvement of
regional lymph nodes (N factor), presence of distant
metastases (M factor), tumor resectability, and survival of
the patients. Additionally, we compared serum levels of
proteins tested in CRC patients with those in 35 CA
patients and 70 healthy controls. Moreover, we deter-
mined the serum levels of the classical tumor marker for
CRC—CEA and CA 19-9.
In the present study, the preoperative serum levels of
MMP-9, TIMP-1, CEA, and CA 19-9 were significantly
higher in the CRC group than in the healthy subjects, what
is in line with results obtained by other authors [7, 16, 17,
21, 29]. Additionally, serum TIMP-1 in CRC patients
increased significantly with tumor stage, N and M factors,
as well as in nonresectable tumors. Our results are in
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Int J Colorectal Dis (2010) 25:1177–1184 1181agreement to the findings of Yukawa et al. [19] who
revealed significant differences in lymph node metastasis,
serosal invasion, curability, and Duke's classification when
clinico-pathological factors between patients with positive
and those with negative TIMP-1 levels were analyzed. It
suggests that the elevated levels of TIMP-1 might reflect
the role of this protein as stimulator of tumor growth and
malignant transformation [12] or anti-apoptotic factor [13]
in colorectal tumor progression.
MMP-9 and TIMP-1 expression in the normal mucosa–
adenoma–dysplasia–adenocarcinoma sequence of the colon
was studied by few authors. Gimeno-Garcia et al. [29]
observed enhanced tissue expression of MMP-9 in patients
with CA in comparison with normal mucosa. They revealed
a significant and progressive increase in the activity of the
latent form of MMP-9 at the different types of colorectal
neoplasma. Herszényi et al. [22] showed that protein
expression of MMP-9 in CRC tissue was significantly
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1182 Int J Colorectal Dis (2010) 25:1177–1184higher compared to adenomas or the normal mucosa, and
staining intensity correlated with the grade of CRC.
Additionally, they observed significantly higher expression
of MMP-9 in adenomas with high grade dysplasia
compared to other adenomas or normal colon. It was
demonstrated that the expression of MMP-9 in adenoma
with high grade dysplasia—CRC sequence was significant-
ly higher when compared to normal tissue. Tomita et al.
showed that TIMP-1 immunoreactivity was detected in
both stromal and epithelial cells in colonic polyps and
adenomas as well as in adenocarcinomas [23].
In the current paper, the clinical significance of serum
MMP-9 and TIMP-1 in the differentiation between CA and
cancer was assessed. Holten-Andersen et al. [30] showed
no differences between TIMP-1 levels in patients with CA
and healthy controls, as well as significantly elevated
concentrations of this protein in patients with colonic or
rectal cancer in comparison with adenoma and healthy
subjects. However, considering the very low number of
cancer patients in their study, the relevance of such
statistical analysis is limited [30]. In our study, serum
levels of TIMP-1 and CEA in adenoma patients were
significantly lower than in CRC patients. Moreover, serum
concentrations of MMP-9 and TIMP-1 were significantly
higher in adenoma patients compared with control group.
The statistical differences between serum levels of TIMP-1
in CA group and CRC patients were confirmed in Dwass–
Steel–Critchlow–Fligner post hoc tests, as well as in
analysis of area under ROC curve for this biomarker. These
results suggest a potential clinical usefulness of pretreat-
ment serum TIMP-1 for the differentiation between
malignant and non-malignant tumors; however, our find-
ings require further studies.
In the present paper, we defined the diagnostic sensitivity
and AUC for all proteins tested to assess a potential clinical
significance of MMP-9 and TIMP-1 as tumor markers in the
diagnosis of CRC. We found that the percentage of elevated
plasma concentrations (diagnostic sensitivity) of TIMP-1
(61%) were higher than those of MMP-9 (55%) and tumor
markers (CEA–39%, CA 19-9–11%). The diagnostic
sensitivity of biomarkers tested increased with their
combined use, and were the highest for TIMP-1 with
MMP-9 (75%) and almost twofold higher (43%) than for
combined use of classical tumor markers for CRC–CEA
with CA 19-9. Moreover, the analysis of ROC curves
indicates the advantage of TIMP-1 measurement over
assessment of classical tumor markers CEA and CA 19-9
in CRC patients. We revealed that area under ROC curve
for determination of TIMP-1 (0.8319) was higher than for
the other biomarkers (CEA, 0.8292; MMP-9, 0.5590; and
CA 19-9, 0.5590) in differentiation between CRC patients
and healthy subjects. The results of AUC for CEA and
CA 19-9 are similar to those obtained in a previous study
concerning diagnostic usefulness classical tumor markers
in CRC patients [31].
In conclusion, the aim of the present study was to
compare the clinical significance of serum MMP-9 with
TIMP-1 in the diagnosis of CRC patients and in the
differentiation between CA and cancer. We found that
serum levels of these proteins were higher in CRC patient
than in healthy subjects. Additionally, serum TIMP-1 was
significantly higher in patients with CRC than in CA
patients. Concentrations of TIMP-1 correlated with tumor
stage, nodal involvement, presence of distant metastases,
patients' survival, and tumor resectability. Diagnostic
sensitivity of TIMP-1 was the highest among the bio-
markers tested. Moreover, the areas under ROC curves of
TIMP-1 were larger than those of MMP-9. Our findings
suggest better usefulness of TIMP-1 than MMP-9 in the
diagnosis of CRC.
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